Dr. Shaker Dakhil, M.D.
Claim this profileAscension Via Christi Hospitals Wichita
About Shaker Dakhil, M.D.
Education:
Earned an MD from St. Joseph University School of Medicine, Beirut, Lebanon, in 1975.
Experience:
Completed Residency in Internal Medicine at Wayne State University, Detroit, Michigan.
Undertook a Fellowship in Hematology/Oncology at the University of Michigan.
Certified in Internal Medicine and Medical Oncology by the American Board of Internal Medicine.
President of the Cancer Center of Kansas since 2000 and a Clinical Professor of Medicine at the University of Kansas School of Medicine – Wichita.
Founder of the Wichita Cancer Foundation and recipient of multiple awards for excellence in oncology.
Area of expertise
Breast Cancer
Shaker Dakhil, M.D. has run 17 trials for Breast Cancer. Some of their research focus areas include:
Lung Cancer
Shaker Dakhil, M.D. has run 16 trials for Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
Ascension Via Christi Hospitals Wichita
Cancer Center Of Kansas - Wichita
Clinical Trials Shaker Dakhil, M.D. is currently running
Multiple Targeted Therapies
for Meningioma
This trial studies four drugs to treat patients with worsening meningioma. These drugs work by blocking enzymes that the tumor cells need to grow. The trial focuses on patients whose tumors have specific genetic mutations.
Recruiting
1 award
Phase 2
10 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting
2 awards
Phase 3
31 criteria
More about Shaker Dakhil, M.D.
Clinical Trial Related
6 years of experience running clinical trials · Led 83 trials as a Principal Investigator · 23 Active Clinical Trials
Treatments Shaker Dakhil, M.D. has experience with
- Carboplatin
- Cisplatin
- Nivolumab
- Paclitaxel
- Pembrolizumab
- Atezolizumab
Breakdown of trials Shaker Dakhil, M.D. has run
Breast Cancer
Lung Cancer
Breast cancer
Non-Small Cell Lung Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Shaker Dakhil, M.D. specialize in?
Shaker Dakhil, M.D. focuses on Breast Cancer and Lung Cancer. In particular, much of their work with Breast Cancer has involved HER2 positive patients, or patients who are HER2 negative.
Is Shaker Dakhil, M.D. currently recruiting for clinical trials?
Yes, Shaker Dakhil, M.D. is currently recruiting for 23 clinical trials in Wichita Kansas. If you're interested in participating, you should apply.
Are there any treatments that Shaker Dakhil, M.D. has studied deeply?
Yes, Shaker Dakhil, M.D. has studied treatments such as Carboplatin, Cisplatin, Nivolumab.
What is the best way to schedule an appointment with Shaker Dakhil, M.D.?
Apply for one of the trials that Shaker Dakhil, M.D. is conducting.
What is the office address of Shaker Dakhil, M.D.?
The office of Shaker Dakhil, M.D. is located at: Ascension Via Christi Hospitals Wichita, Wichita, Kansas 67214 United States. This is the address for their practice at the Ascension Via Christi Hospitals Wichita.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.